Jon Amund Kyte | |||||||||||||||||||||||||||||||||||||||||
Professor Kyte is Head of the Department for Clinical Cancer Research, Oslo University Hospital — NORWAY | |||||||||||||||||||||||||||||||||||||||||
Jon A Kyte has combined expertise as clinical oncologist and immunotherapy researcher, and is Head of the Department for Clinical Cancer Research, Oslo University Hospital, and Professor in Clinical Research at Oslo Metropolitan University. Kyte is also Research Group Leader for «Immunotherapy Against Solid Cancers» at Department for Cancer Immunology, Insitute of Cancer Research, Oslo University Hospital. The Department for Clinical Cancer Research → cancertrials.no includes the largest Early Phase Trial Unit in Norway, as well as a Clinical Trial Office and Study Nurse Unit, and currently conducts more than100 clinical trials in oncology. Dr. Kyte did his PhD and training for oncologist at Oslo University Hospital, followed by a postdoc in T cell therapy at University College London. Kyte has experience as breast cancer consultant, is currently a consultant at the Early Phase Trial Unit and has initiated and conducted several clinical trials combining immunological checkpoint inhibitors with chemotherapy or radiotherapy. The Kyte research group → ous-research.no/kyte conduct laboratory research based on material from immunotherapy trials, aimed at personalized cancer immunotherapy. Further, the group develops tumor-targeting chimeric antigen receptors (CARs) for T cell therapy against solid cancers, as well as strategies designed to make the CAR T cells resistant to immune suppression. |